Would you like to participate ask a question join the surfers in our next episode?

S2-E23 – Wrapping Up Day Two Of The Fourth Global NASH Congress — Drugs, Lifestyles and Health Policy

Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise and Roger as they keep discussing Day Two of the 4th Global NASH Congress

On April 29, over 175 NASH stakeholders from across the globe met virtually to hear 20 presentations from leaders in academia and industry. SurfingNASH selected 9 presentations to discuss in a session recorded right after the conference concluded. When the five panelists got together, the discussion extended to 90 minutes…too long for a single episode.

Episode 23 features Suneil Hosmane discussing lifestyle and exercise, Ian Rowe discuss public policy in the US Veterans Health system, and Ian and Roger Green reviewing three developmental drugs discussions from the conference. Louise Campbell lends perspective throughout. Stimulating…engaging…”can’t miss.”

TOPICS: aldafermin, cirrhosis, EchoSens, Fatty Liver, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Genfit, Madrigal, NAFLD, NASH, NGM Biopharmaceuticals, non-invasive liver testing, social policy, Tawazun Health, resmetirom, Hepion Pharmaceuticals, CRV431, US Veterans Health Administration, Lifestyle Interventions

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request Transcript of This Episode
Request Transcript

NASH & Diabetes Podcast and NASH Tsunami Podcast